Stan Neil Finkelstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fuzzy Logic | 2 | 2015 | 57 | 0.930 |
Why?
|
Intensive Care Units | 7 | 2021 | 3744 | 0.850 |
Why?
|
Drug Repositioning | 2 | 2022 | 233 | 0.730 |
Why?
|
Absorbable Implants | 1 | 2021 | 338 | 0.640 |
Why?
|
Antihypertensive Agents | 2 | 2022 | 2024 | 0.440 |
Why?
|
Influenza, Human | 3 | 2016 | 1521 | 0.410 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2021 | 1116 | 0.360 |
Why?
|
Commerce | 1 | 2016 | 607 | 0.350 |
Why?
|
Fluid Therapy | 1 | 2013 | 579 | 0.330 |
Why?
|
Career Choice | 1 | 2016 | 756 | 0.330 |
Why?
|
Laboratories | 1 | 2012 | 458 | 0.320 |
Why?
|
Histamine H1 Antagonists | 2 | 1999 | 100 | 0.320 |
Why?
|
Decision Support Systems, Clinical | 2 | 2019 | 1175 | 0.310 |
Why?
|
Triage | 3 | 2020 | 986 | 0.310 |
Why?
|
Blood Transfusion | 4 | 2021 | 1301 | 0.310 |
Why?
|
Efficiency | 8 | 2005 | 476 | 0.300 |
Why?
|
Health Resources | 2 | 2011 | 935 | 0.300 |
Why?
|
Models, Theoretical | 2 | 2021 | 3575 | 0.300 |
Why?
|
Influenza Vaccines | 2 | 2016 | 768 | 0.300 |
Why?
|
Economics, Pharmaceutical | 1 | 2007 | 87 | 0.280 |
Why?
|
Artificial Intelligence | 3 | 2021 | 2578 | 0.280 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 445 | 0.280 |
Why?
|
Health Benefit Plans, Employee | 2 | 2000 | 333 | 0.280 |
Why?
|
Education, Medical, Undergraduate | 1 | 2016 | 1070 | 0.270 |
Why?
|
Pancreatitis | 1 | 2013 | 1096 | 0.270 |
Why?
|
Databases, Factual | 5 | 2022 | 7968 | 0.260 |
Why?
|
Models, Statistical | 3 | 2022 | 5079 | 0.260 |
Why?
|
Drug Costs | 7 | 2004 | 1183 | 0.260 |
Why?
|
Cost of Illness | 7 | 2005 | 1937 | 0.250 |
Why?
|
Disaster Planning | 1 | 2011 | 557 | 0.250 |
Why?
|
Home Care Services | 1 | 2011 | 648 | 0.240 |
Why?
|
Patient Admission | 4 | 2020 | 1367 | 0.230 |
Why?
|
Primary Prevention | 1 | 2011 | 1186 | 0.230 |
Why?
|
Anemia | 3 | 2005 | 1509 | 0.220 |
Why?
|
Decision Support Techniques | 1 | 2013 | 1998 | 0.220 |
Why?
|
Disease Outbreaks | 2 | 2017 | 1749 | 0.210 |
Why?
|
Students, Medical | 1 | 2016 | 1936 | 0.200 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 3879 | 0.200 |
Why?
|
Antidepressive Agents | 4 | 2004 | 2897 | 0.200 |
Why?
|
Health Expenditures | 4 | 2005 | 2366 | 0.200 |
Why?
|
Pneumonia | 1 | 2013 | 2143 | 0.190 |
Why?
|
Stroke Volume | 1 | 2015 | 5496 | 0.190 |
Why?
|
Computer Simulation | 2 | 2022 | 6241 | 0.190 |
Why?
|
Drug Industry | 2 | 2007 | 788 | 0.180 |
Why?
|
Erythropoietin | 3 | 2005 | 719 | 0.180 |
Why?
|
Achilles Tendon | 1 | 2022 | 180 | 0.170 |
Why?
|
Work Capacity Evaluation | 1 | 1999 | 44 | 0.170 |
Why?
|
Systems Analysis | 1 | 2020 | 169 | 0.160 |
Why?
|
Bayes Theorem | 1 | 2007 | 2330 | 0.160 |
Why?
|
Causality | 2 | 2022 | 1242 | 0.160 |
Why?
|
Tendon Injuries | 1 | 2022 | 328 | 0.160 |
Why?
|
Sickness Impact Profile | 1 | 1999 | 299 | 0.150 |
Why?
|
Public Health | 1 | 2011 | 2669 | 0.150 |
Why?
|
Anterior Cruciate Ligament | 1 | 2021 | 423 | 0.150 |
Why?
|
Respiratory Hypersensitivity | 1 | 1999 | 273 | 0.150 |
Why?
|
Bone Screws | 1 | 2021 | 532 | 0.150 |
Why?
|
Blood Glucose | 3 | 2021 | 6391 | 0.150 |
Why?
|
Biotechnology | 1 | 2019 | 282 | 0.140 |
Why?
|
Imipramine | 2 | 2000 | 98 | 0.140 |
Why?
|
1-Naphthylamine | 1 | 1996 | 49 | 0.130 |
Why?
|
Insulin | 2 | 2021 | 6597 | 0.130 |
Why?
|
Forecasting | 2 | 2020 | 2928 | 0.130 |
Why?
|
Costs and Cost Analysis | 4 | 2018 | 1668 | 0.130 |
Why?
|
Sleep Stages | 1 | 1999 | 694 | 0.130 |
Why?
|
Antineoplastic Agents | 5 | 2007 | 13642 | 0.130 |
Why?
|
Metformin | 1 | 2022 | 906 | 0.120 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2007 | 326 | 0.120 |
Why?
|
Drug Utilization | 4 | 2004 | 1188 | 0.120 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2019 | 3415 | 0.120 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2019 | 740 | 0.120 |
Why?
|
Electronic Health Records | 2 | 2022 | 4811 | 0.110 |
Why?
|
Depressive Disorder | 5 | 2002 | 3728 | 0.110 |
Why?
|
ROC Curve | 3 | 2021 | 3578 | 0.110 |
Why?
|
Acid-Base Imbalance | 1 | 2013 | 41 | 0.110 |
Why?
|
Humans | 57 | 2022 | 761596 | 0.110 |
Why?
|
Health Services Accessibility | 1 | 2011 | 5440 | 0.110 |
Why?
|
Hypoglycemia | 1 | 2020 | 883 | 0.110 |
Why?
|
United States | 24 | 2020 | 72340 | 0.100 |
Why?
|
Insulin-Secreting Cells | 1 | 2019 | 901 | 0.100 |
Why?
|
Cyclohexanols | 2 | 2002 | 126 | 0.100 |
Why?
|
Medical Errors | 1 | 2020 | 1263 | 0.100 |
Why?
|
Absenteeism | 5 | 2000 | 247 | 0.100 |
Why?
|
Employee Performance Appraisal | 2 | 2005 | 86 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2020 | 1376 | 0.100 |
Why?
|
Deductibles and Coinsurance | 2 | 2004 | 316 | 0.100 |
Why?
|
Home Nursing | 1 | 2011 | 92 | 0.090 |
Why?
|
Hypoglycemic Agents | 2 | 2022 | 3085 | 0.090 |
Why?
|
Heart Failure | 1 | 2015 | 11671 | 0.090 |
Why?
|
Drug Prescriptions | 3 | 2006 | 1670 | 0.090 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 244 | 0.090 |
Why?
|
Health Promotion | 1 | 2003 | 2214 | 0.090 |
Why?
|
Platelet Count | 1 | 2013 | 781 | 0.090 |
Why?
|
Portugal | 2 | 2020 | 91 | 0.090 |
Why?
|
Cost-Benefit Analysis | 7 | 2022 | 5493 | 0.090 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 654 | 0.080 |
Why?
|
Leukocyte Count | 1 | 2013 | 1596 | 0.080 |
Why?
|
Depression | 3 | 2004 | 8126 | 0.080 |
Why?
|
Lactic Acid | 1 | 2013 | 1139 | 0.080 |
Why?
|
Dementia | 1 | 2022 | 2689 | 0.080 |
Why?
|
Cross Infection | 1 | 2017 | 1422 | 0.070 |
Why?
|
Retrospective Studies | 13 | 2020 | 80647 | 0.070 |
Why?
|
Hospitals | 2 | 2020 | 3883 | 0.070 |
Why?
|
Critical Illness | 1 | 2020 | 2723 | 0.070 |
Why?
|
Health Care Costs | 5 | 2002 | 3242 | 0.070 |
Why?
|
Culture Media | 2 | 2019 | 897 | 0.070 |
Why?
|
Family Health | 1 | 2011 | 1257 | 0.070 |
Why?
|
Students | 1 | 2016 | 1741 | 0.070 |
Why?
|
Drug Labeling | 2 | 2006 | 248 | 0.070 |
Why?
|
Respiration | 1 | 2012 | 1656 | 0.070 |
Why?
|
Risk Assessment | 4 | 2020 | 23996 | 0.070 |
Why?
|
Temperature | 1 | 2012 | 2226 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10212 | 0.060 |
Why?
|
Hepatitis | 2 | 1979 | 228 | 0.060 |
Why?
|
Male | 26 | 2021 | 360846 | 0.060 |
Why?
|
Emergency Service, Hospital | 3 | 2020 | 7879 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1779 | 0.060 |
Why?
|
Blood Donors | 2 | 1979 | 345 | 0.060 |
Why?
|
Female | 27 | 2021 | 392705 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2012 | 14665 | 0.060 |
Why?
|
Hemodynamics | 1 | 2015 | 4160 | 0.060 |
Why?
|
Severity of Illness Index | 4 | 2015 | 15843 | 0.060 |
Why?
|
Health Maintenance Organizations | 2 | 2004 | 659 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3384 | 0.060 |
Why?
|
Neoplasms | 5 | 2007 | 22173 | 0.060 |
Why?
|
Medicare Part B | 1 | 2005 | 117 | 0.060 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2004 | 174 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2016 | 7828 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2007 | 857 | 0.050 |
Why?
|
Child Health Services | 1 | 2009 | 646 | 0.050 |
Why?
|
Anxiety | 3 | 2002 | 4573 | 0.050 |
Why?
|
Pharmacogenetics | 1 | 2006 | 675 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 4016 | 0.050 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2004 | 348 | 0.050 |
Why?
|
Depressive Disorder, Major | 3 | 2004 | 4762 | 0.050 |
Why?
|
Adult | 21 | 2020 | 221210 | 0.050 |
Why?
|
Tendon Transfer | 1 | 2022 | 124 | 0.050 |
Why?
|
Employer Health Costs | 3 | 1995 | 21 | 0.050 |
Why?
|
Mental Disorders | 2 | 2000 | 6845 | 0.050 |
Why?
|
Heart Rate | 1 | 2012 | 4195 | 0.050 |
Why?
|
Natural Language Processing | 2 | 2020 | 1163 | 0.050 |
Why?
|
Oxygen | 1 | 2012 | 4227 | 0.050 |
Why?
|
Sulfonylurea Compounds | 1 | 2022 | 219 | 0.050 |
Why?
|
Rupture | 1 | 2022 | 443 | 0.050 |
Why?
|
Drug Resistance | 2 | 2004 | 1596 | 0.050 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2007 | 617 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2004 | 429 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2005 | 741 | 0.040 |
Why?
|
Middle Aged | 18 | 2020 | 220921 | 0.040 |
Why?
|
Health Services Research | 2 | 2004 | 1812 | 0.040 |
Why?
|
Coronavirus Infections | 1 | 2017 | 3086 | 0.040 |
Why?
|
Hospitals, Pediatric | 1 | 2009 | 1860 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2013 | 5293 | 0.040 |
Why?
|
Managed Care Programs | 2 | 2002 | 940 | 0.040 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2002 | 489 | 0.040 |
Why?
|
Prognosis | 2 | 2020 | 29629 | 0.040 |
Why?
|
Workplace | 3 | 1999 | 863 | 0.040 |
Why?
|
Sertraline | 2 | 2000 | 209 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 12149 | 0.040 |
Why?
|
Legislation, Medical | 1 | 1979 | 98 | 0.040 |
Why?
|
Aged | 12 | 2020 | 169310 | 0.040 |
Why?
|
Comorbidity | 6 | 2004 | 10508 | 0.040 |
Why?
|
Blood Pressure | 1 | 2013 | 8481 | 0.040 |
Why?
|
Chronic Disease | 5 | 2009 | 9319 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2005 | 6534 | 0.040 |
Why?
|
Logistic Models | 3 | 2020 | 13255 | 0.040 |
Why?
|
Medical Records | 1 | 2022 | 1408 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2006 | 12059 | 0.030 |
Why?
|
Headache | 1 | 2005 | 1256 | 0.030 |
Why?
|
Ventilation | 1 | 2017 | 128 | 0.030 |
Why?
|
Organizational Policy | 1 | 1999 | 432 | 0.030 |
Why?
|
Asthma | 3 | 2006 | 6234 | 0.030 |
Why?
|
Occupational Diseases | 1 | 2005 | 1490 | 0.030 |
Why?
|
Regression Analysis | 3 | 2002 | 6345 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15266 | 0.030 |
Why?
|
Models, Economic | 3 | 2007 | 716 | 0.030 |
Why?
|
Piperazines | 1 | 2007 | 2523 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2003 | 2707 | 0.030 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2019 | 467 | 0.030 |
Why?
|
Cohort Studies | 2 | 2020 | 41495 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2004 | 1590 | 0.030 |
Why?
|
Republic of Korea | 1 | 2017 | 590 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2003 | 1089 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14033 | 0.030 |
Why?
|
Pyrimidines | 1 | 2007 | 3028 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2020 | 58984 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2011 | 5337 | 0.030 |
Why?
|
Cell Separation | 1 | 2018 | 1720 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 1999 | 1722 | 0.030 |
Why?
|
Young Adult | 2 | 2016 | 59260 | 0.030 |
Why?
|
Pluripotent Stem Cells | 1 | 2019 | 799 | 0.030 |
Why?
|
Migraine Disorders | 1 | 2005 | 1703 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 1996 | 763 | 0.020 |
Why?
|
Insurance, Health | 1 | 2004 | 2499 | 0.020 |
Why?
|
Universities | 1 | 2016 | 993 | 0.020 |
Why?
|
Telemedicine | 1 | 2009 | 3052 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2018 | 1668 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 9469 | 0.020 |
Why?
|
Environment | 1 | 2017 | 1123 | 0.020 |
Why?
|
Hypnotics and Sedatives | 1 | 1999 | 1179 | 0.020 |
Why?
|
Models, Econometric | 2 | 2004 | 216 | 0.020 |
Why?
|
Sex Factors | 3 | 2000 | 10554 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1600 | 0.020 |
Why?
|
Anti-Asthmatic Agents | 2 | 2006 | 574 | 0.020 |
Why?
|
Heart Arrest | 1 | 2020 | 1514 | 0.020 |
Why?
|
Risk | 2 | 2004 | 9610 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2002 | 3600 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13367 | 0.020 |
Why?
|
Multiple Sclerosis | 1 | 2004 | 3222 | 0.020 |
Why?
|
Adolescent | 9 | 2009 | 88326 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2002 | 3206 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1642 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2019 | 1923 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 1999 | 2720 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 8002 | 0.020 |
Why?
|
Bipolar Disorder | 2 | 2002 | 5092 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54423 | 0.020 |
Why?
|
Medicare | 1 | 2005 | 6770 | 0.020 |
Why?
|
Amitriptyline | 1 | 2006 | 112 | 0.020 |
Why?
|
Physicians | 1 | 2004 | 4591 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1996 | 6019 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2006 | 140 | 0.020 |
Why?
|
Health Status | 1 | 1998 | 4077 | 0.020 |
Why?
|
Drug Utilization Review | 1 | 2006 | 248 | 0.020 |
Why?
|
Statistics as Topic | 2 | 2005 | 2358 | 0.020 |
Why?
|
Amines | 1 | 2006 | 281 | 0.010 |
Why?
|
Doxazosin | 1 | 2004 | 18 | 0.010 |
Why?
|
Chicago | 1 | 2005 | 254 | 0.010 |
Why?
|
Episode of Care | 1 | 2005 | 128 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2007 | 629 | 0.010 |
Why?
|
Hypertension | 1 | 2004 | 8540 | 0.010 |
Why?
|
Insurance Claim Reporting | 1 | 2004 | 166 | 0.010 |
Why?
|
Health Planning | 1 | 2004 | 230 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2004 | 64685 | 0.010 |
Why?
|
Age Factors | 1 | 1999 | 18399 | 0.010 |
Why?
|
Hospitalization | 2 | 2020 | 10721 | 0.010 |
Why?
|
Insurance Benefits | 1 | 2004 | 187 | 0.010 |
Why?
|
Educational Status | 2 | 2000 | 2522 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 2003 | 345 | 0.010 |
Why?
|
Evidence-Based Medicine | 2 | 2004 | 3688 | 0.010 |
Why?
|
Financing, Personal | 1 | 2004 | 309 | 0.010 |
Why?
|
Utilization Review | 1 | 2002 | 382 | 0.010 |
Why?
|
Benzamides | 1 | 2007 | 1371 | 0.010 |
Why?
|
Cost Savings | 1 | 2006 | 913 | 0.010 |
Why?
|
Intention | 1 | 2004 | 347 | 0.010 |
Why?
|
Age of Onset | 2 | 2000 | 3306 | 0.010 |
Why?
|
Combined Modality Therapy | 2 | 2004 | 8527 | 0.010 |
Why?
|
Cardiovascular Agents | 1 | 2006 | 840 | 0.010 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2006 | 1141 | 0.010 |
Why?
|
Cost Allocation | 1 | 1999 | 49 | 0.010 |
Why?
|
Direct Service Costs | 1 | 1999 | 59 | 0.010 |
Why?
|
Infant | 3 | 2009 | 36193 | 0.010 |
Why?
|
Censuses | 1 | 2000 | 202 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39106 | 0.010 |
Why?
|
Fee-for-Service Plans | 1 | 2004 | 700 | 0.010 |
Why?
|
Health Services | 1 | 2004 | 752 | 0.010 |
Why?
|
Drugs, Generic | 1 | 2004 | 448 | 0.010 |
Why?
|
Child, Preschool | 3 | 2009 | 42232 | 0.010 |
Why?
|
Child | 5 | 2009 | 80158 | 0.010 |
Why?
|
Blood Banks | 1 | 1979 | 108 | 0.010 |
Why?
|
Marital Status | 1 | 1999 | 426 | 0.010 |
Why?
|
Treatment Failure | 1 | 2004 | 2643 | 0.010 |
Why?
|
Ambulatory Care | 2 | 2002 | 2775 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1664 | 0.010 |
Why?
|
Psychotropic Drugs | 1 | 2002 | 888 | 0.010 |
Why?
|
Prevalence | 3 | 2004 | 15733 | 0.010 |
Why?
|
Pandemics | 1 | 2016 | 8656 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2006 | 1906 | 0.010 |
Why?
|
Hospital Costs | 1 | 2002 | 947 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 74213 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2009 | 26202 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 2002 | 14608 | 0.010 |
Why?
|
Fees and Charges | 1 | 1977 | 192 | 0.010 |
Why?
|
Data Collection | 1 | 2005 | 3322 | 0.010 |
Why?
|
Liability, Legal | 1 | 1977 | 210 | 0.010 |
Why?
|
Altruism | 1 | 1977 | 208 | 0.010 |
Why?
|
Psychotherapy | 1 | 2004 | 1647 | 0.010 |
Why?
|
Family Characteristics | 1 | 1999 | 1004 | 0.010 |
Why?
|
Survival Analysis | 1 | 2007 | 10090 | 0.010 |
Why?
|
Economics | 1 | 1993 | 141 | 0.010 |
Why?
|
Employment | 1 | 1999 | 1118 | 0.010 |
Why?
|
Public Policy | 1 | 1977 | 559 | 0.010 |
Why?
|
Prescription Fees | 1 | 1993 | 153 | 0.010 |
Why?
|
Patient Compliance | 1 | 2002 | 2690 | 0.010 |
Why?
|
Income | 1 | 2000 | 1877 | 0.010 |
Why?
|
Massachusetts | 1 | 2004 | 8833 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2004 | 12463 | 0.010 |
Why?
|
Pain Measurement | 1 | 1999 | 3551 | 0.010 |
Why?
|
Health Policy | 1 | 1979 | 2684 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12341 | 0.000 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1993 | 2199 | 0.000 |
Why?
|
Suicide | 1 | 1993 | 1602 | 0.000 |
Why?
|
Time Factors | 1 | 2004 | 39969 | 0.000 |
Why?
|
Arthritis, Rheumatoid | 1 | 1995 | 3763 | 0.000 |
Why?
|
Coronary Disease | 1 | 1993 | 5914 | 0.000 |
Why?
|